BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34980322)

  • 21. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 22. Hyperoxia-induced methylation decreases RUNX3 in a newborn rat model of bronchopulmonary dysplasia.
    Zhu Y; Fu J; Yang H; Pan Y; Yao L; Xue X
    Respir Res; 2015 Jun; 16(1):75. PubMed ID: 26104385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-600 mediates EZH2/RUNX3 signal axis to modulate breast cancer cell viability and sorafenib sensitivity.
    Zhao Q; Li D; Feng J; Jinsihan D
    J Biochem Mol Toxicol; 2024 Jan; 38(1):e23613. PubMed ID: 38229326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
    Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
    Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
    Wang C; Liu Z; Woo CW; Li Z; Wang L; Wei JS; Marquez VE; Bates SE; Jin Q; Khan J; Ge K; Thiele CJ
    Cancer Res; 2012 Jan; 72(1):315-24. PubMed ID: 22068036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 29. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
    Gao YH; Lin JZ; An X; Luo JL; Cai MY; Cai PQ; Kong LH; Liu GC; Tang JH; Chen G; Pan ZZ; Ding PR
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1153-60. PubMed ID: 25442042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
    Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
    Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of short duration radiotherapy combined with chemotherapy for advanced rectal cancer.
    Gao SQ; Zhang YC; Zhang C; Wang SJ; Ren W; Yuan N; Wen JY
    World J Clin Cases; 2021 Mar; 9(7):1524-1531. PubMed ID: 33728296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
    Dang X; Ma A; Yang L; Hu H; Zhu B; Shang D; Chen T; Luo Y
    Cancer Genet; 2012 Mar; 205(3):113-23. PubMed ID: 22469510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor Regression Grade as a Prognostic Factor in Metastatic Colon Cancer Following Preoperative Chemotherapy.
    Yang Y; Luo D; Zhang R; Cai S; Li Q; Li X
    Clin Colorectal Cancer; 2022 Jun; 21(2):96-106. PubMed ID: 34895989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The value of MRI with CUBE sequence in early evaluation of the efficacy of neoadjuvant therapy for locally advanced rectal cancer].
    Wang X; Cao W; Liu D; Li F; Li W; Kang L; Deng Y; Zhou Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Jan; 21(1):73-78. PubMed ID: 29354903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Krill L; Deng W; Eskander R; Mutch D; Zweizig S; Hoang B; Ioffe O; Randall L; Lankes H; Miller DS; Birrer M
    Gynecol Oncol; 2020 Feb; 156(2):423-429. PubMed ID: 31843273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
    Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
    Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EZH2 Protein Expression in Estrogen Receptor Positive Invasive Breast Cancer Treated With Neoadjuvant Endocrine Therapy: An Exploratory Study of Association With Tumor Response.
    Gan Y; Lo Y; Makower D; Kleer C; Lu J; Fineberg S
    Appl Immunohistochem Mol Morphol; 2022 Oct; 30(9):614-622. PubMed ID: 36048167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-130-5p promotes invasion as well as migration of lung adenocarcinoma cells by targeting the EZH2 signaling pathway.
    Zhang G; Wu YJ; Yan F
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9480-9488. PubMed ID: 31773700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
    Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
    Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.